Loading...
Loading...
BTX| Name | Value |
|---|---|
| Revenues | 47.0K |
| Cost of Revenue | 673.0K |
| Gross Profit | -626.0K |
| Operating Expense | 4,305.0K |
| Operating I/L | -4,931.0K |
| Other Income/Expense | -595.0K |
| Interest Income | 0.0K |
| Pretax | -5,526.0K |
| Income Tax Expense | 3.0K |
| Net Income/Loss | -5,529.0K |
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Its flagship program, IRX-2, is currently undergoing a Phase 2b clinical trial for patients with squamous cell cancer of the head and neck. The company also leverages gene-editing and cell therapy technology to develop treatments for oncology, blood disorders, and monogenic diseases, catering to a diverse range of medical needs.
